Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-613 plus modified FOLFIRINOX versus FOLFIRINOX in metastatic pancreatic adenocarcinoma
2018-001587-32Phase 3Completed
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of devimistat in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Cornerstone Pharmaceuticals. Primary endpoint: Overall Response Rate. Started Feb 2019; status: completed.
02
Drugs
devimistat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2018-001587-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001587-32.